{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.64","value":"61.19"},{"groupId":"OG001","spread":"20.02","value":"60.10"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"134"},{"groupId":"OG001","value":"137"}],"units":"Participants"}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.03","value":"-1.45"},{"groupId":"OG001","spread":"22.42","value":"-1.22"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"109"},{"groupId":"OG001","value":"123"}],"units":"Participants"}],"title":"Day 1: Cycle 3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.26","value":"-0.12"},{"groupId":"OG001","spread":"18.28","value":"-0.16"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"102"}],"units":"Participants"}],"title":"Day 1: Cycle 6"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.97","value":"1.06"},{"groupId":"OG001","spread":"20.99","value":"0.41"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"55"},{"groupId":"OG001","value":"82"}],"units":"Participants"}],"title":"Day 1: Cycle 9"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.36","value":"-9.17"},{"groupId":"OG001","spread":"19.29","value":"-1.92"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"13"}],"units":"Participants"}],"title":"Day 1: Cycle 17"}],"denoms":[{"counts":[{"groupId":"OG000","value":"134"},{"groupId":"OG001","value":"139"}],"units":"Participants"}],"description":"EORTC-Quality of Life Questionnaire (QLQ)-C30 is a cancer-specific instrument with 30 questions for evaluation of new chemotherapy and provides an assessment of participant reported outcome dimensions. EORTC QLQ-C30 included GHS/ QOL, functional scales (physical, role, cognitive, emotional, social), symptom scales (fatigue, pain, nausea/vomiting), and 6 single items (dyspnea, appetite loss, insomnia, constipation, diarrhea, financial difficulties). Most questions from QLQ-C30 were a 4-point scale (1/Not at All to 4/Very Much), except Items 29-30, which comprise GHS scale and were a 7-point scale (1/Very Poor to 7/Excellent). Answers were converted into grading scale, with values between 0 and 100. A high score represented a favorable outcome with a best quality of life for participant.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received pomalidomide 4 mg PO on Days 1 to 21 of each 28-day treatment cycle plus dexamethasone 40 mg (participants \\>= 75 years of age received 20 mg dexamethasone) PO on Days 1, 8, 15 and 22 of each 28-day treatment cycle until disease progression or unacceptable toxicity or participant's wish to discontinue study treatment, or any other reason, whichever comes first (maximum exposure: 73.7 weeks).","id":"OG000","title":"Pd (Pomalidomide + Dexamethasone)"},{"description":"Participants received isatuximab 10 mg/kg IV infusion on Days 1, 8, 15, and 22 at Cycle 1, and then on Days 1 and 15 of subsequent cycles plus pomalidomide 4 mg PO on Days 1 to 21 of each 28-day treatment cycle and dexamethasone 40 mg (participants \\>= 75 years of age received 20 mg dexamethasone), PO or IV on Day 1, 8, 15, 22 of each 28-day treatment cycle until disease progression or unacceptable toxicity or participant's wish to discontinue study treatment, or any other reason, whichever comes first (maximum exposure: 76.7 weeks).","id":"OG001","title":"IPd (Isatuximab + Pomalidomide + Dexamethasone)"}],"paramType":"MEAN","populationDescription":"Analysis was performed on safety population evaluable for global health status. Here, 'Number analyzed' = participants with available data for each specified category.","reportingStatus":"POSTED","timeFrame":"Baseline, Day 1 of each cycle (Cycle 3, Cycle 6, Cycle 9, and Cycle 17)","title":"Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Cancer Specific Questionnaire With 30 Items (EORTC QLQ-C30): Global Health Status (GHS)/Quality of Life (QOL) Score","type":"SECONDARY","unitOfMeasure":"score on a scale"}